3 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Lymphocytic Leukemia: new trials by email Literature Review of Lymphocytic Leukemia trials Research Report on Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients Lirilumab, Rituximab - Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 7 | 2015-06-23 | 2020-05-28 |
| Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma alemtuzumab, everolimus - Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Mayo Clinic | 28 | 2009-07-01 | 2017-09-26 |
| Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab Lenalidomide, Rituximab - Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 29 | 2007-10-01 | 2015-09-17 |
Leukemia, Lymphoid (3) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Recurrence (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Leukemia (2) · Chronic Disease (1) · Disease Attributes (1) · Leukemia, B-Cell (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms by Site (1)
Rituximab (2) · Alemtuzumab (1) · Everolimus (1) · Lenalidomide (1) · lirilumab (1)
H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1)
United States (3)
Clive S. Zent, M.D. (1) · Javier Pinilla, M.D., PhD. (1) · Jose F. Leis, M.D. (1) · Nitin Jain, MBBS (1)